Patent application number | Description | Published |
20090010840 | BISPECIFIC SINGLE CHAIN Fv ANTIBODY MOLECULES AND METHODS OF USE THEREOF - Bispecific single chain antibody molecules are disclosed which may be used to advantage to treat various forms of cancer associated with the overexpression of members of the EGFR protein family. | 01-08-2009 |
20090010841 | PROSTATE CANCER SPECIFIC INTERNALIZING HUMAN ANTIBODIES - This invention provides novel prostate cancer specific internalizing human antibodies. The antibodies are useful by themselves to prevent growth and/or proliferation of prostate cancer cells. The antibodies can also be formulated as chimeric molecules to direct an effector (e.g. a cytotoxin, an imaging reagent, a drug, etc.) to a prostate tumor site. | 01-08-2009 |
20090105086 | Methods of selecting internalizing antibodies - This invention provides methods of selecting antibodies that are internalized into target cells. The methods generally involve contacting target cells with one or more members of an antibody phage display library. The members of the phage display library are also contacted with cells of a subtractive cell line. The target cells are then washed to remove the subtractive cell line cells and members of the phage display library that are non-specifically bound or weakly bound to the target cells. The target cells are cultured under conditions where members of the phage display library can be internalized if bound to an internalizing marker and internalized members of the phage display library are then identified. | 04-23-2009 |
20090123481 | THERAPEUTIC MONOCLONAL ANTIBODIES THAT NEUTRALIZE BOTULINUM NEUROTOXINS - This invention provides antibodies that specifically bind to and neutralize botulinum neurotoxin type A (BoNT/A) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism. | 05-14-2009 |
20090324606 | THERAPEUTIC MONOCLONAL ANTIBODIES THAT NEUTRALIZE BOTULINUM NEUROTOXINS - This invention provides antibodies that specifically bind to and neutralize botulinum neurotoxin type A (BoNT/A) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism. | 12-31-2009 |
20100008978 | NANOPARTICLES EFFECTIVE FOR INTERNALIZATION INTO CELLS - This invention provides antibodies that have improved affinity for the epidermal growth factor receptor (EGFR). In addition, this invention provides microparticles and nanoparticles comprising a plurality of EGFR affinity moieties that are effectively internalized by cells expressing an EGFR. | 01-14-2010 |
20100009390 | MUTANT ANTIBODIES WITH HIGH AFFINITY FOR EGFR - This invention provides antibodies that have improved affinity for the epidermal growth factor receptor (EGFR). In addition, this invention provides microparticles and nanoparticles comprising a plurality of EGFR affinity moieties that are effectively internalized by cells expressing an EGFR. | 01-14-2010 |
20100166773 | THERAPEUTIC MONOCLONAL ANTIBODIES THAT NEUTRALIZE BOTULINUM NEUROTOXINS - This invention provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism. | 07-01-2010 |
20100196265 | ANTI-EGFR FAMILY ANTIBODIES, BISPECIFIC ANTI-EGFR FAMILY ANTIBODIES AND METHODS OF USE THEREOF - Anti-EGFR family member antibodies and bispecific antibodies comprising one or more anti-EGFR family member antibodies are disclosed. These antibodies can be used to advantage to specifically target forms of cancer associated with the overexpression of members of the EGFR protein family. | 08-05-2010 |
20100233165 | INTERNALIZING HUMAN MONOCLONAL ANTIBODIES TARGETING PROSTATE CANCER CELLS IN SITU - This invention provides a method that allows selection of antibodies against cells (e.g., tumor cells) in situ using laser capture microdissection. By restricting antibody selection to binders of internalizing epitopes, a panel of phage antibodies was generated that targets clinically represented prostate cancer antigens. | 09-16-2010 |
20100297004 | HIGH AFFINITY ANTI-PROSTATE STEM CELL ANTIGEN (PSCA) ANTIBODIES FOR CANCER TARGETING AND DETECTION - The present invention provides novel high affinity antibodies and fragments thereof that bind to the cancer antigen PSCA. The antibodies of the present invention may be used for cancer diagnosis, prognosis, treatment, visualization, and the like. The present invention also provides methods for the detection, visualization, and treatment of various cancers expressing PSCA. | 11-25-2010 |
20110171235 | THERAPEUTIC MONOCLONAL ANTIBODIES THAT NEUTRALIZE BOTULINUM NEUROTOXINS - This invention provides antibodies that specifically bind to and neutralize botulinum neurotoxin type A (BoNT/A) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism. | 07-14-2011 |
20110200615 | Antibodies that Neutralize Botulinum Neurotoxins - This disclosure provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism. | 08-18-2011 |
20110218333 | Internalizing ErbB2 antibodies - This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided. | 09-08-2011 |
20120039915 | GLIOBLASTOMA MULTIFORME-REACTIVE ANTIBODIES AND METHODS OF USE THEREOF - The present disclosure is generally related to antibodies that bind specifically to glioblastoma multiforme (GBM) cells. In particular, the present disclosure provides compositions comprising human single chain or full-length antibodies that bind tumor cells. Additionally the present disclosure provides methods of using the anti-GBM antibodies. | 02-16-2012 |
20120177663 | Therapeutic Monoclonal Antibodies that Neutralize Botulinum Neurotoxins - This invention provides antibodies that specifically bind to and neutralize botulinum neurotoxin type A (BoNT/A) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism. | 07-12-2012 |
20120269822 | Anti-Botulinum Neurotoxin a Single Domain Antibody Antibodies - Antibodies that bind to | 10-25-2012 |
20130045206 | ANTIBODIES DIRECTED AGAINST THE TRANSFERRIN RECEPTOR AND USES THEREOF FOR IMMUNOTHERAPY OF IRON-DEPENDENT TUMOURS - The present invention relates to a molecular structure characterised in that said structure includes at least one amino acid sequence selected from: SEQ. ID NO.: 1, SEQ. ID NO.: 2, SEQ. ID NO.: 3, SEQ. ID NO.: 4, SEQ. ID NO.: 5, SEQ. ID NO.: 6, SEQ. ID NO.: 7, SEQ. ID NO.: 8, SEQ. ID NO.: 9, SEQ. ID NO.: 10, SEQ. ID NO.: 11, SEQ. ID NO.: 12, SEQ. ID NO.: 13, SEQ. ID NO.: 14, SEQ. ID NO.: 15, SEQ. ID NO.: 16, SEQ. ID NO.: 17, SEQ. ID NO.: 18, SEQ. ID NO.: 19, SEQ. ID NO.: 20, SEQ. ID NO.: 21, SEQ. ID NO.: 22, SEQ. ID NO.: 23, SEQ. ID NO.: 24, SEQ. ID NO.: 25, SEQ. ID NO.: 26, SEQ. ID NO.: 27, SEQ. ID NO.: 28, SEQ. ID NO.: 29, SEQ. ID NO.: 30, SEQ. ID NO.: 31, SEQ. ID NO.: 32, SEQ. ID NO.: 33, SEQ. ID NO.: 34, SEQ. ID NO.: 35, SEQ. ID NO.: 36, said amino acid sequence corresponding to an antigen complementarity determining region (CDR) of the variable domain of the heavy chain (CDR-H) or the light chain (CDR-L) of an antibody targeting the human transferrin receptor (TfR). The present invention also relates to a pharmaceutical composition including a therapeutically effective amount of at least one molecular structure as defined in the present application, combined with a pharmaceutically acceptable carrier. | 02-21-2013 |
20130064837 | INTEGRIN ALPHA-V BETA8 NEUTRALIZING ANTIBODY - The present invention relates to ανβ8 antagonists, anti-ανβ8 antibodies or immunoconjugates for reducing TGFβ activation in an individual. Further provided are compositions comprising one of the ανβ8 antagonists, anti-ανβ8 antibodies or immunoconjugates, methods for using the compositions, and related subject matter. | 03-14-2013 |
20130202603 | BISPECIFIC SINGLE CHAIN Fv ANTIBODY MOLECULES AND METHODS OF USE THEREOF - Bispecific single chain antibody molecules are disclosed which may be used to advantage to treat various forms of cancer associated with the overexpression of members of the EGFR protein family. | 08-08-2013 |
20130209481 | Anti-Tumor Antigen Antibodies and Methods of Use - Antibodies that bind to tumor associated antigen CD44 or to tumor associated antigen EphA2, are disclosed herein, as well as related compositions and methods of use. Methods of use encompass cancer therapies, diagnostics, and screening methods. | 08-15-2013 |
20130337039 | Internalizing ErBB2 Antibodies - This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided. | 12-19-2013 |
20140105910 | Therapeutic Monoclonal Antibodies that Neutralize Botulinum Neurotoxins - This invention provides antibodies that specifically bind to and typically neutralize | 04-17-2014 |
20150030600 | Antibodies for Botulinum Neurotoxins - The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism. | 01-29-2015 |
20150071937 | INTERNALIZING HUMAN MONOCLONAL ANTIBODIES TARGETING PROSTATE CANCER CELLS IN SITU - This invention provides a method that allows selection of antibodies against cells (e.g., tumor cells) in situ using laser capture microdissection. By restricting antibody selection to binders of internalizing epitopes, a panel of phage antibodies was generated that targets clinically represented prostate cancer antigens. | 03-12-2015 |